Curaleaf: Canccord Slashes Price Target, Anticipates Headwinds For 2022

Earlier this month, Curaleaf Holdings, Inc. (CSE: CURA reported its fourth quarter and full year 2021 results. The company announced that its revenue grew 93% on a year over year basis to $1.2 billion with gross profits of $588 million or a 48.5% margin. Adjusted EBITDA meanwhile grew to $298 million, up 107% year over year.

A number of analysts slashed their 12-month price target on Curaleaf after the results, bringing the average 12-month price target to C$20.18, down from $24.10 last month. The company currently has 16 analysts covering the stock with 5 having strong buy ratings, 9 having buy ratings, and 2 analysts having hold ratings. The street high sits at C$27, which represents a 250% upside to the current stock price.

In Canaccord’s fourth quarter review, they reiterate their buy rating but lower their 12-month price target from C$18 to C$15.50, saying that Curaleaf reported better than expected margins on a decelerating revenue base. Overall, Canaccord was surprised to see how strong margins came in with the company citing a number of different margin pressures such as wholesale pricing and supply chain inflation.

On the results, Canaccord expected revenues of $324.7 million, above the actual $320 million estimates, with the company missing Cannacords estimate with $320.0 million in Q4 revenues. Though the company saw better gross margins, coming in at $159 million versus Canaccord’s $155 million estimates. Canaccord says that the revenue miss is largely attributed to a decrease in all legal U.S cannabis sales by 4% in the fourth quarter, while the modest ~$3 million sequential growth came from new stores in Florida and Arizona.

For the better than expected gross margin, Canaccord calls this number impressive as the space has seen a lot of pricing pressures throughout many of the states Curaleaf has production in. With that, they note that Curaleaf does continue to generate more than 70% of its revenue through vertically integrated retail sales which will take longer to see any pricing pressures.

Curaleaf’s 2022 guidance currently estimates full year revenues to come in between $1.4 and $1.5 billion, adjusted EBITDA margins of 28%, and positive cash flow from operations for the full year. Canaccord says that the revenue estimate is roughly 8% below the consensus estimate which points to the growth headwinds continuing into this year.

Below you can see Canaccord’s updated 2022 estimates.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Goliath Resources Hits 10.60 g/t Gold Over 22.82 Metres, Highest Grade Results In Third Distinct Rock Package At Surebet Discovery

Four Countries Control the Fertilizer That Feeds the World | Sage Potash

$10,000 Gold Is Just A Question of Time | Florian Grummes

Recommended

Antimony Resources Drills 5.27% Sb Over 4.95 Metres In Latest Results

Nord Precious Metals Identifies 29 Veins At Castle East Following 3D Modeling

Related News

BMO Lifts GFL Environmental Price Target To $46 After Strong Results

This month, GFL Environmental Inc. (TSX: GFL) reported its third quarter financial results. The company...

Tuesday, November 23, 2021, 04:22:00 PM

Canaccord Genuity Resumes Coverage On Xebec Adsorption With C$6 Price Target

This morning Canaccord Genuity resumed their coverage on Xebec Adsorption (TSXV: XBC) with a Speculative...

Thursday, September 17, 2020, 01:15:32 PM

BMO Sees Positivity In Latest Rogers Communications Financial Results

On October 21st at 11:28 PM, Rogers Communications (TSX: RCI) announced a change of directors...

Friday, October 29, 2021, 04:05:00 PM

Alphabet: Consensus Earnings Estimates For Q1 2021

Alphabet (NASDAQ: GOOG) will be reporting their first quarter financial results on April 27th after...

Monday, April 26, 2021, 11:44:00 AM

MediPharm Labs: Canaccord Slashes Price Target Following Q4 Results

Earlier this week, Medipharm Labs (TSX: LABS) reported their fourth quarter and 2020 year-end financial...

Friday, April 2, 2021, 09:00:00 AM